New Small-cap Buy and Sell Ideas for Oppenheimer's 50/50 List
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Is Viking Therapeutics Inc. (VKTX) the Best Performing Small-Cap Stock in 2024?
Oppenheimer points out the next "trend" for weight loss drugs: oral over-the-counter medication.
The competition to develop oral weight-loss drugs is intensifying.
